Top 2% Biotech Avidity Tumbles Despite 'Positive' Results In Treating Muscular Dystrophy

Top 2% Biotech Avidity Tumbles Despite 'Positive' Results In Treating Muscular Dystrophy

Top 2% Biotech Avidity Tumbles Despite 'Positive' Results In Treating Muscular Dystrophy · Investor's Business Daily
Trade RNA on Coinbase

Top-notch biotech stock Avidity tumbled Monday despite unveiling "positive" midstage test results for its muscular dystrophy treatment.